PepGen (NASDAQ:PEPG) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of PepGen (NASDAQ:PEPG – Free Report) from a hold rating to a sell rating in a report released on Sunday morning,Wall Street Zen reports.

Several other brokerages also recently issued reports on PEPG. HC Wainwright reissued a “buy” rating on shares of PepGen in a report on Wednesday, September 9th. Weiss Ratings raised PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Wedbush upped their price objective on shares of PepGen from $4.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, November 11th. Bank of America upgraded PepGen from an “underperform” rating to a “neutral” rating and raised their price objective for the stock from $2.50 to $6.00 in a research report on Tuesday, November 10th. Finally, Guggenheim increased their price objective on PepGen from $7.00 to $15.00 and gave the stock a “buy” rating in a report on Friday. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.40.

View Our Latest Stock Analysis on PEPG

PepGen Stock Performance

Shares of PepGen stock opened at $4.36 on Friday. The stock has a market capitalization of $301.97 million, a P/E ratio of -4.07 and a beta of 2.02. PepGen has a twelve month low of $1.31 and a twelve month high of $7.80. The business’s fifty day moving average price is $2.80 and its 200 day moving average price is $2.97.

PepGen (NASDAQ:PEPG – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). As a group, sell-side analysts predict that PepGen will post -1.13 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Group One Trading LLC bought a new stake in PepGen during the first quarter worth about $77,000. Seven Fleet Capital Management LP acquired a new position in shares of PepGen during the first quarter worth approximately $105,000. Jump Financial LLC acquired a new position in shares of PepGen during the third quarter worth approximately $114,000. Rangeley Capital LLC grew its stake in shares of PepGen by 88.1% during the first quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock valued at $121,000 after purchasing an additional 31,896 shares during the last quarter. Finally, Persistent Asset Partners Ltd bought a new stake in shares of PepGen during the second quarter valued at approximately $171,000. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

(Get Free Report)

PepGen is a clinical-stage biotechnology company developing oligonucleotide medicines for people with neuromuscular diseases. Its Enhanced Delivery Oligonucleotide (EDO) platform is designed to help deliver these medicines to muscle tissue. The company’s pipeline includes PGN-EDO51, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping, and PGN-EDODM1, an investigational candidate for myotonic dystrophy type 1.

Featured Articles

Analyst Recommendations for PepGen (NASDAQ:PEPG)

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.